ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1765

Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis

Yasuhiro Shimojima1, Dai Kishida2 and Yoshiki Sekijima2, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANCA, APRIL, BAFF, IgG4 Related Disease and biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis – ANCA-Associated Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of dura mater. It has been recognized that ANCA-associated vasculitis is the underlying disease as the common cause of HP whose histopathology indicates inflammatory cells infiltration and granulomatous lesion as well as fibrosis; meanwhile, definite immune-mediated mechanism is still elusive. In this study, we demonstrated the useful cerebrospinal fluid (CSF) biomarkers in ANCA-related HP (ANCA-HP).

Methods: We reviewed the clinical records of 22 Japanese patients with immune-mediated HP (mean age, 65 years; 9 women and 13 men). They were divided into patients with ANCA-HP (n = 11), or those with other autoimmune disorders related HP (other HP) including IgG4-related disease/multifocal fibrosclerosis (n = 4), relapsing polychondritis (n = 1), sarcoidosis (n = 2), and idiopathic HP (n = 4). HP associated with infection and/or neoplasm was excluded in this study. As the controls, 11 patients with multiple sclerosis (MS) and 8 with non-inflammatory neurological disorders (NIND) were enrolled. The routine laboratory examinations of serum C-reactive protein (CRP) levels and CSF, including cell counts, protein levels, and IgG-index were detected. In addition, B-cell activation factor of the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) in the CSF and serum samples were measured using commercially available ELISA kits. To determine the characteristics of ANCA-HP, the laboratory data from them were statistically compared between patients with ANCA-HP, other HP, and controls.

Results: CSF levels of BAFF and APRIL were significantly higher in patients with both ANCA-HP and other HP than in patients with MS and NIND (p < 0.05). Serum levels of BAFF and APRIL were significantly higher in patients with both ANCA-HP and other HP than in patients with NIND (p < 0.05). In patients with both ANCA-HP and other HP, neither BAFF nor APRIL expression indicated no correlation between in the CSF and serum, suggesting that BAFF and APRIL were locally produced within the central nervous system (CNS). Meanwhile, both BAFF and APRIL expression in the CSF significantly demonstrated the correlation with IgG-index in patients with ANCA-HP (p < 0.05). In patients with other HP, BAFF and APRIL expression in the CSF had significant correlation with cell counts and protein levels (p < 0.05).

Conclusion: BAFF and APRIL expression in the CSF is associated with disease activity as the immunological biomarker in immune-mediated HP. Furthermore, it was suggested that increased levels of BAFF and APRIL produced in the CNS may impact on developing ANCA-HP by promoting the B cell lineage.


Disclosure: Y. Shimojima, None; D. Kishida, None; Y. Sekijima, None.

To cite this abstract in AMA style:

Shimojima Y, Kishida D, Sekijima Y. Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cerebrospinal-fluid-biomarker-of-disease-activity-significance-in-anca-related-hypertrophic-pachymeningitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cerebrospinal-fluid-biomarker-of-disease-activity-significance-in-anca-related-hypertrophic-pachymeningitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology